FI931097A0 - Laekemedel, deras framstaellning och anvaendning vid bekaempning av smaertor och/eller inflammationen hos maenniskor och djur - Google Patents

Laekemedel, deras framstaellning och anvaendning vid bekaempning av smaertor och/eller inflammationen hos maenniskor och djur

Info

Publication number
FI931097A0
FI931097A0 FI931097A FI931097A FI931097A0 FI 931097 A0 FI931097 A0 FI 931097A0 FI 931097 A FI931097 A FI 931097A FI 931097 A FI931097 A FI 931097A FI 931097 A0 FI931097 A0 FI 931097A0
Authority
FI
Finland
Prior art keywords
och
smaertor
maenniskor
inflammationen
bekaempning
Prior art date
Application number
FI931097A
Other languages
English (en)
Other versions
FI103180B (fi
FI103180B1 (fi
FI931097A (fi
Inventor
Gerd Geisslinger
Kay Brune
Original Assignee
Paz Arzneimittelentwicklung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6414093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI931097(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paz Arzneimittelentwicklung filed Critical Paz Arzneimittelentwicklung
Publication of FI931097A publication Critical patent/FI931097A/fi
Publication of FI931097A0 publication Critical patent/FI931097A0/fi
Application granted granted Critical
Publication of FI103180B publication Critical patent/FI103180B/fi
Publication of FI103180B1 publication Critical patent/FI103180B1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI931097A 1990-09-12 1993-03-11 Flurbiprofeenia sisältävien lääkkeiden valmistus kipujen ja/tai tulehdusten torjumiseksi eläimissä ja ihmisissä FI103180B1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4028906A DE4028906A1 (de) 1990-09-12 1990-09-12 Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
PCT/EP1991/001568 WO1992004018A1 (de) 1990-09-12 1991-08-19 Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen

Publications (4)

Publication Number Publication Date
FI931097A FI931097A (fi) 1993-03-11
FI931097A0 true FI931097A0 (fi) 1993-03-11
FI103180B FI103180B (fi) 1999-05-14
FI103180B1 FI103180B1 (fi) 1999-05-14

Family

ID=6414093

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931097A FI103180B1 (fi) 1990-09-12 1993-03-11 Flurbiprofeenia sisältävien lääkkeiden valmistus kipujen ja/tai tulehdusten torjumiseksi eläimissä ja ihmisissä

Country Status (14)

Country Link
US (2) US5206029A (fi)
EP (1) EP0607128B2 (fi)
JP (1) JP3305315B2 (fi)
AT (1) ATE158182T1 (fi)
AU (1) AU654498B2 (fi)
CA (1) CA2087723C (fi)
DE (2) DE4028906A1 (fi)
DK (1) DK0607128T4 (fi)
ES (1) ES2106785T5 (fi)
FI (1) FI103180B1 (fi)
GR (1) GR3025502T3 (fi)
HU (1) HU225887B1 (fi)
RU (1) RU2080116C1 (fi)
WO (1) WO1992004018A1 (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4216756C2 (de) * 1992-05-21 1994-08-25 Pharmatrans Sanaq Ag 2-Arylpropionsäure-Zubereitungen und Verfahren zu ihrer Herstellung
RU2133733C1 (ru) * 1992-12-02 1999-07-27 Дзе бутс компани ПЛС. Способ получения фенилпропионовой кислоты
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
JP3782834B2 (ja) * 1994-10-26 2006-06-07 株式会社トクホン 鎮痛抗炎症貼付剤
IT1271800B (it) * 1994-12-27 1997-06-09 Zambon Spa Processo di preparazione degli enantiomeri dell'acido 2- (2-fluoro- 4-bifenil) propionico
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
AT408067B (de) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
GB9523833D0 (en) * 1995-11-22 1996-01-24 Boots Co Plc Medical treatment
US5702720A (en) * 1995-12-22 1997-12-30 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of flurbiprofen
DK0966277T3 (da) * 1997-03-10 2006-03-27 Univ Loma Linda Med Anvendelse af R-NSAID'er til forebyggelse af Alzheimer's sygdom
GB9705989D0 (en) * 1997-03-22 1997-05-07 Boots Co Plc Therapeutic composition
WO2000013684A2 (en) 1998-09-03 2000-03-16 Loma Linda University Medical Center Pharmaceutical composition and method for treatment of inflammation
AU2004222809B2 (en) * 1998-09-03 2007-06-28 Loma Linda University Medical Center Pharmaceutical Composition and Method for Treatment of Inflammation
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
US20080021085A1 (en) * 2000-04-13 2008-01-24 Mayo Foundation For Medical Education And Research Method of reducing abeta42 and treating diseases
DE10047319A1 (de) 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
DE60213230T2 (de) 2001-05-21 2006-11-23 Alcon Inc. Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US7247328B2 (en) * 2002-05-31 2007-07-24 Zinpro Corporation Chromium (III) alpha amino acid complexes
US7129375B2 (en) * 2002-10-16 2006-10-31 Zinpro Corporation Metal complexes of α amino dicarboxylic acids
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US6953507B2 (en) * 2003-03-21 2005-10-11 Ecolab Inc. Low temperature cleaning
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US20050171207A1 (en) * 2003-09-26 2005-08-04 Myriad Genetics, Incorporated Method and composition for combination treatment of neurodegenerative disorders
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
US20070042094A1 (en) 2005-08-22 2007-02-22 Alcide Corporation Oxidation method and compositions therefor
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20090162421A1 (en) * 2007-12-21 2009-06-25 Paz Arzneimittel-Entwicklungsgesellschaft Mbh Drugs as well as their production and use in the treatment of pain-associated neuropathies
JP2011506505A (ja) * 2007-12-21 2011-03-03 ペー アー ツェット アルツナイミッテルエントヴィックルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 痛みを伴う神経障害の治療の際の、医薬並びにその製造方法及び使用
MX2011008660A (es) 2009-07-24 2011-09-22 Mika Pharma Ges Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Metodo de desarrollo de composicion liquida para aplicacion en la piel como espuma y composicion aplicable topicamente.
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9578879B1 (en) 2014-02-07 2017-02-28 Gojo Industries, Inc. Compositions and methods having improved efficacy against spores and other organisms
CN113262216A (zh) * 2020-02-14 2021-08-17 北京泰德制药股份有限公司 一种用于消除皮表红肿镇痛的外用制剂
CN118125916A (zh) * 2022-09-23 2024-06-04 南京知和医药科技有限公司 一种s-（+）-氟比洛芬盐及其制备方法、药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784705A (en) * 1964-01-24 1974-01-08 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
CS222255B2 (en) * 1977-03-08 1983-06-24 Boots Co Ltd Method of increasing the portion of the deisred anantiometer in the acid component of the 2-arylpropion acid
US4209638A (en) * 1977-03-08 1980-06-24 The Boots Company Limited Preparation of therapeutic agents
ZA828453B (en) † 1981-12-08 1983-12-28 Boots Co Plc Therapeutic agents
JPS6283885A (ja) † 1985-10-08 1987-04-17 Nitto Electric Ind Co Ltd 酵素固定膜及びその製造方法
US4927854A (en) * 1987-12-24 1990-05-22 Analgesic Associates Sustained/enhanced analgesia
AU6758990A (en) † 1989-11-06 1991-05-31 Sepracor, Inc. Analgesic composition containing optically pure s(+) flurbiprofen

Also Published As

Publication number Publication date
EP0607128B2 (de) 2007-02-21
HUT63564A (en) 1993-09-28
GR3025502T3 (en) 1998-02-27
AU8335291A (en) 1992-03-30
CA2087723C (en) 2002-07-23
DE4028906A1 (de) 1992-03-19
RU2080116C1 (ru) 1997-05-27
JPH06500313A (ja) 1994-01-13
WO1992004018A1 (de) 1992-03-19
AU654498B2 (en) 1994-11-10
DK0607128T4 (da) 2007-05-07
DK0607128T3 (da) 1998-04-14
EP0607128B1 (de) 1997-09-17
DE4028906C2 (fi) 1992-10-29
DE59108854D1 (de) 1997-10-23
ES2106785T3 (es) 1997-11-16
FI103180B (fi) 1999-05-14
ATE158182T1 (de) 1997-10-15
JP3305315B2 (ja) 2002-07-22
ES2106785T5 (es) 2007-10-16
US5206029A (en) 1993-04-27
CA2087723A1 (en) 1992-03-13
FI103180B1 (fi) 1999-05-14
FI931097A (fi) 1993-03-11
HU225887B1 (en) 2007-11-28
US5200198A (en) 1993-04-06
EP0607128A1 (de) 1994-07-27
HU9300636D0 (en) 1993-05-28

Similar Documents

Publication Publication Date Title
FI931097A0 (fi) Laekemedel, deras framstaellning och anvaendning vid bekaempning av smaertor och/eller inflammationen hos maenniskor och djur
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
NO306850B1 (no) Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom
DE69206876D1 (de) Nukleosidanalogen enthaltende Antiviren-Zubereitungen
SE8406538D0 (sv) Novel derivatives of purine
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
IT1237999B (it) Trattamento di malattie associate ad infezioni di hiv
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
ES2044843T3 (es) Uso de antibioticos de quinolona y naftiridina en la preparacion de medicamentos oftalmicos.
KR950701820A (ko) 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
RU95103436A (ru) Способ замедления прогрессирования атеросклероза коронарных артерий с помощью правастатина
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
FI913625A0 (fi) Behandling av nedsatt funktion av leukocyter med gm-csf.
ES2071143T3 (es) Factores b1, b2, c1, c2, d1, d2, e y t del antibiotico ge 2270.
IT1239064B (it) Uso terapeutico del dipiridamolo
FI952018A (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskriptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
ATE92760T1 (de) Verwendung des thiazol-derivates tiprotimod zur herstellung eines mittels zur therapie von virusinfektionen.
PT84996A (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen
SE8404556D0 (sv) Farmaceutisk komposition
DE3854158D1 (de) Nucleosid-analoge.
DK0814813T3 (da) Anvendelse af penciclovir til behandling af human herpesvirus-8
ES2131105T3 (es) Composiciones farmaceuticas de pentapeptidos y procedimientos de uso de las mismas.
FI941707A0 (fi) Naftokinoninen käyttö P. carinii -infektioiden hoitoon ja profylaksiaan